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Background and Purpose: Dravet syndrome is a severe, genetic form of paediatric
epilepsy associated with premature mortality and co-morbidities such as anxiety,
depression, autism, motor dysfunction and memory deficits. Cannabidiol is an
approved anticonvulsive drug in the United States and Europe for seizures associated
with Dravet syndrome in patients 2 years of age and older. We investigated its
potential to prevent premature mortality and improve associated co-morbidities.
Experimental Approach: The efficacy of sub-chronic cannabidiol administration in
two mouse models of Dravet syndrome was investigated. The effect of cannabidiol
on neonatal welfare and survival was studied using Scn1a−/− mice. We then used a
hybrid, heterozygote Scn1a+/− mouse model to study the effect of cannabidiol on
survival and behavioural co-morbidities: motor deficits (rotarod and static-beam test),
gait abnormality (gait test), social anxiety (social interaction test), anxiety-like
(elevated plus maze) and depressive-like behaviours (sucrose preference test) and
cognitive impairment (radial arm maze test).
Key Results: In Scn1a−/− mice, cannabidiol increased survival and delayed worsening
of neonatal welfare. In Scn1a+/− mice, chronic cannabidiol administration did not
show any adverse effect on motor function and gait, reduced premature mortality,
improved social behaviour and memory function, and reduced anxiety-like and
depressive-like behaviours.
Conclusion and Implications: We are the first to demonstrate a potential disease-
modifying effect of cannabidiol in animal models of Dravet syndrome. Cannabidiol
treatment reduced premature mortality and improved several behavioural co-
morbidities in Dravet syndrome mice. These crucial findings may be translated into
human therapy to address behavioural co-morbidities associated with Dravet
syndrome.
Abbreviations: AED, Anti-epileptic Drug; ASPA, Animals (Scientific Procedures)Act; CBD, cannabidiol; TNW, Total Neonatal Welfare.
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1 | INTRODUCTION
Dravet syndrome is a severe form of myoclonic epilepsy in children
(Dravet, Bureau, Oguni, Fukuyama, & Cokar, 2005). It is typically trig-
gered by a fever which initiates the first generalised or partial seizure
at usually 6 to 9 months of age (Dravet et al., 2005). During the first
year of life, seizures are relatively infrequent but over time, can lead
to status epilepticus. In subsequent years, the symptoms become more
severe with generalised tonic–clonic, myoclonic, absence and focal
seizures being common, status epilepticus rarely occurs after 10 years
of age (Akiyama, Kobayashi, Yoshinaga, & Ohtsuka, 2010). The SCN1A
gene encodes NaV1.1, a voltage-gated sodium channel, which plays a
pivotal role in Dravet syndrome where 70–80% of patients exhibit a
deletion or mutation (truncating, missense, or splice site mutations
leading to loss of function) of this gene on chromosome 2q (Harkin
et al., 2007; Marini et al., 2011).
In addition to seizures, premature mortality occurs in approxi-
mately 21% Dravet syndrome patients (Dravet et al., 2005; Genton,
Velizarova, & Dravet, 2011). Patients also exhibit multiple
co-morbidities including psychomotor delay, gait abnormality, hyper-
activity, attention deficits, autism, sleep disorders, anxiety, depression,
language impairment and severe cognitive deficits, profoundly
affecting quality of life (Genton et al., 2011). The current standard
treatment includes the combination of two or more antiepileptic
drugs, such as benzodiazepines, valproic acid, topiramate,
levetiracetam and stiripentol (Devinsky et al., 2017). However, these
drugs often fail to adequately control seizures and are associated with
severe drug-induced motor and psychiatric adverse effects including
anxiety, depression and memory impairments (Chen et al., 2017;
Ristic, Vojvodic, Jankovic, Sindelic, & Sokic, 2006).
Cannabidiol (CBD) is one of the most abundant plant-derived
cannabinoids. It is non-euphoric and has shown potential for use in
treating seizures, epilepsy, epileptogenesis and related
neuroprotection in a number of animal models including Dravet syn-
drome (Kaplan, Stella, Catterall, & Westenbroek, 2017; Patra et al.,
2019; Rosenberg, Patra, & Whalley, 2017). CBD was demonstrated to
be an effective anticonvulsant in Phase 3 clinical trials for the treat-
ment of Dravet syndrome and Lennox Gastaut Syndrome and in 2018
received FDA approval in the United States for seizures associated
with these disorders (Devinsky et al., 2017; FDA, 2018; Thiele et al.,
2018). However, little is known about its potential effect on the
premature mortality and co-morbidities associated with Dravet
syndrome.
Here, we first evaluated the effect of CBD on survival and neona-
tal welfare in Scn1a−/− knockout mice Scn1a−/− mice are obtained
from mice with a 129S background. They differ from human Dravet
syndrome by their complete loss of expression of NaV1.1 channels,
but they reproduce the ataxia, seizures and premature mortality
commonly observed in Dravet syndrome patients (Kalume, Yu,
Westenbroek, Scheuer, & Catterall, 2007; Yu et al., 2006). They
exhibit symptoms such as seizures, ataxia and a poor righting reflex
from post-natal day 9 (P9) onwards which become progressively
worse over time, with animals typically dying before they reach P16
(Kalume et al., 2007; Miller, Hawkins, McCollom, & Kearney, 2014; Yu
et al., 2006). Due to the extreme severity and early mortality, this
model is not suitable for studying complex behavioural co-morbidities
but does allow rapid assessment of antiepileptic drug (AED) efficacy
and was used here as a proof-of-concept for CBD efficacy.
We then conducted a study in the hybrid heterozygote Scn1a+/−
mouse Dravet model to investigate the effect of chronic CBD treat-
ment in prevention of premature mortality and a range of complex
behavioural co-morbidities such as motor impairment, anxiety, depres-
sion, social and memory deficits. This model of Dravet syndrome uses
a hybrid heterozygote Scn1a+/− mouse model breeding male
heterozygotic mice from a 129S background with female wild-type
(WT) mice from the C57/Black six (C57/B6) background. The resul-
tant heterozygote offspring recapitulate several features of Dravet
syndrome including seizures, premature mortality and co-morbidities
such as social deficit, anxiety and memory impairments (Han et al.,
2012; Yu et al., 2006). They are considered a standard model to study
drug effects on Dravet syndrome and complex behavioural co-
morbidities (Anderson, Hawkins, Thompson, Kearney, & George,
2017; Hawkins et al., 2017; Kaplan et al., 2017).
2 | METHODS
Animal studies are reported in compliance with the ARRIVE guidelines
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the
recommendations made by the British Journal of Pharmacology and UK
Home Office regulations (Animals [Scientific Procedures] Act, 1986;
What is already known about this subject
• Dravet syndrome is associated with premature mortality,
seizures and associated co-morbidities.
• Cannabidiol's (CBD's) anticonvulsive action in Dravet syn-
drome has been demonstrated in preclinical and clinical
studies.
What this study adds
• Chronic CBD administration reduces premature mortality
in two mouse models of Dravet syndrome.
• This study demonstrates that CBD improves co-
morbidities in a mouse model of Dravet syndrome.
What is the clinical significance
• CBD may improve survival in human Dravet syndrome
patients.
• CBD may be a suitable treatment to reduce the possibil-
ity of behavioural co-morbidities in human Dravet syn-
drome patients.
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ASPA) under licence 70/8397 “Mouse Model of Dravet Syndrome”
and were approved by the Animal Welfare and Ethics Review Board
at the University of Reading (McGrath & Lilley, 2015). The study used
a total of 182 mice: 95 in Study I (19 for the development of the sur-
vival algorithm, 36 for breeding/colony maintenance and 40 for the
study) and 87 in Study II (15 for breeding/colony maintenance, 52 in
test groups, and a further 20 WT “novel” animals for social interaction
test). All mice were maintained in 12 hr:12 hr light:dark cycle, a room
temperature of 21C and humidity of 50 ± 10%, with ad libitum access
to food and water. Both male and female mice were used in all experi-
mental groups.
2.1 | Study I: Assessment of neonatal welfare and
survival in Scn1a−/− mice
2.1.1 | Animals
129S-Scn1atm1Kea/Mmjax (RRID:MMRRC_037107-JAX) heterozygote
mice (Jackson Laboratory, USA) were maintained in the
BioResource Unit at the University of Reading (UK) and bred
together to obtain Scn1a−/− and WT animals used for this study
(n = 10 per group; Figure 1a). All experiments were conducted dur-
ing light phase 8:00 a.m.–8:00 p.m. The maternal behaviour (see
Table S1) of the dams was also assessed simultaneously to ensure
that any of the parameters observed in the study animals
(Scn1a−/−/WT mice) were not affected by the dam's behaviour. In
this study, dam scores remained 0 throughout the study and so
the responses of the pups were not considered to have been
affected by variations in maternal behaviours. At the end of the
study, animals were humanely killed by a Schedule 1 method (cer-
vical dislocation).
2.1.2 | Experimental design
Following genotyping (see supplementary material 1), animals were
randomly divided into four groups: WT vehicle treated, WT CBD
treated, Scn1a−/− vehicle treated, and Scn1a−/− CBD treated
F IGURE 1 Schematic showing the timeline of the drug administration and behavioural tests. (a) Timeline of drug administration and welfare
scoring in Study I. The wild-type (WT) and Scn1a−/− mice were injected (s.c.) twice daily with either vehicle or CBD (100 mgkg−1) from post-natal
day 8 (P8) to P25/death. Twice daily welfare scoring was conducted in all the groups throughout the experimental period. (b) Timeline of drug
administration and co-morbidity tests in Study II. The Scn1a−/− mice were injected (s.c.) twice daily with either vehicle or CBD (100 mgkg−1) from
P8 to P52/death. AWT vehicle-treated control group was also taken. Social interaction (P35–P37), sucrose preference (P39–P41), elevated plus
maze (EPM; P42) and motor function and radial arm maze (RAM; P45–P52) tests were conducted in all the groups
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(n = 10 per group). They were injected subcutaneously twice daily
with either CBD (100 mgkg−1) or its vehicle (ethanol: Kolliphor®:
0.9% saline = 2:1:17) from P8 until P25 or death (whichever
was earlier). A twice daily welfare check was conducted throughout
the entire duration of the study. Drug administration was con-
ducted at 08:00 a.m. and followed by welfare checks. Conversely,
afternoon welfare checks were conducted from 04:00 p.m. and
followed by drug administration in order to provide the maximum
possible time between doses. The experimental timeline is depicted
in Figure 1a.
2.1.3 | Assessment of welfare scores
Welfare scoring of neonates was conducted twice daily using a
blinded spreadsheet that lacks the information on the genotype of
the animals and the treatment (CBD/vehicle) given to them, to
ensure the experimenter remained blind to both treatment and
genotype. Neonatal welfare scoring (Table S2) was based upon a
previously validated standardised approach used widely in murine
models (Langford et al., 2010; Ullman-Culleré & Foltz, 1999;
Wolfensohn & Lloyd, 2007). Here, the parameters used for the
welfare assessment were weight, natural activity (NA; 0–3),
reflex/response to touch (RT; 0–3), orbital tightening (OT; 0–2),
body condition (BC) score (1–3) and surface temperature (ST; 0–2;
data not shown). Finally, a total neonatal welfare (TNW) score
(range 0–8) was calculated by adding together scores from NA, RT
and ST. CBD treatment significantly delayed the worsening of NA,
RT, OT, BC and TNW scores in the Scn1a−/− mice compared to
their vehicle-treated counterparts. For clarity only, the TNW data
have been reported in this manuscript; the rest of the welfare data
have been supplied in Figure S2.
2.1.4 | Assessment of survival
Animal suffering was minimised by employing a validated, welfare
scoring system (Table S2) alongside a mathematical model to pre-
dict death; see Data S2 and Data S3 for the original welfare data
used to construct the model (Animals 1–19 only) and the welfare
data for animals used in the study. In this way, any animal for
which the model predicted death could be killed 0.5 day before
enduring the maximal severity of the disease and enabling us to
comply with welfare requirements of ASPA. The model used an
algorithm to predict death based on prior data obtained from
untreated Scn1a−/− mice (n = 19) that exhibited the maximum
severity of the disease and died a natural death (Data S3). In this
algorithm, the thresholds for each parameter (TNW, NA, RT, OT
and BC scores) to predict death were obtained using the following
procedure: (i) Each parameter, measured every half day from birth
for each animal, is averaged with a moving mean with a 1.5-day
window; (ii) the least severe score for each parameter observed
across the 19 animals over 0.5 day before their death was found;
(iii) each of the five parameters exhibited by the animals in the
study was compared to scores obtained in (ii) twice a day; (iv) if
each of the five parameters reached their respective threshold
defined in (ii) at least once since P8, the animal would undergo a
Schedule 1 procedure (cervical dislocation) within 0.5 day. Addi-
tionally, ST threshold was employed such that if the sum of the ST
scores over the last 1.5 days was equal to or greater than 3, the
animal would be killed by Schedule 1 procedure (cervical disloca-
tion) within 0.5 day.
2.2 | Study II: Assessment of survival and co-
morbidities in Scn1a+/− mice
2.2.1 | Animals
The animals were group housed throughout the study except for
3 days during sucrose preference test when each animal was indi-
vidually housed. This study was conducted in a reversed dark:light
cycle with all experiments performed in the dark cycle (dim red
light, 8:00 a.m.–8:00 p.m.). Male 129S-Scn1atm1Kea/Mmjax heterozy-
gote mice (Jackson Laboratory, USA) maintained in the Bio-
Resource Unit, University of Reading (UK), were bred with female
WT C57BL/6 mice (Charles River, UK; RRID:MGI:5656552) to
obtain Scn1a+/− and WT littermate mice used in this study. At the
end of the study, animals were humanely killed by a Schedule
1 method (cervical dislocation).
2.2.2 | Experimental design
Here, hybrid Scn1a+/− of both sexes was randomly divided into
two groups and subcutaneously injected with either CBD
(100 mgkg−1 twice daily; n = 12) or its vehicle (ethanol:
Kolliphor®:0.9% saline = 2:1:17; n = 29) from P8 onwards until
P52 or death (whichever was earlier). Similarly, WT littermate mice
(n = 11) were injected with vehicle for the entire period of the
study. Given that a significant number of deaths (~60%) were
predicted to occur between P20–P27 in vehicle-treated Scn1a+/−, a
larger initial group size was utilised to obtain a minimum n = 10
animals per group for behavioural assessment from P35 onwards.
Of note, we accounted the possibility that CBD-treated animals
might also die; therefore, in the first run, equal group sizes were
taken. However, the mortality was higher in the vehicle-treated
Scn1a+/− group than in the CBD-treated Scn1a+/− group, so in sub-
sequent runs, a greater number of animals were included in the
vehicle-treated Scn1a+/− group. The experimental timeline has been
depicted in Figure 1b.
2.2.3 | Assessment of survival
As seizure-related deaths in this model were unpredictable, animals
were video monitored continuously (24 hr × 7 days) throughout
the study, and any mortality observed was cross-checked with the
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available video footage (1 hr prior to death) to confirm the reason
of death.
2.2.4 | Assessment of motor function
Fine motor control in animals were assessed by the accelerated
rotarod and static beam tests. Animals were habituated to the sta-
tionary rotarod for 2 min a day for 2 days. In the accelerated
rotarod test, each mouse was placed individually on a linearly
accelerating rod (4–40 rpm over 5 min; LE8500, Letica Scientific
Instruments, UK), and average latency to fall from the rod (maxi-
mum 300 s) was calculated from three consecutive trials (2 min
interval between trials).
The static beam task was further employed to analyse balance
and coordination (Sedy, Urdzikova, Jendelova, & Sykova, 2008),
where the animals were required to walk along a cylindrical ele-
vated beam (100 cm long, 0.9 cm diameter, and 50 cm height from
floor) and enter a dark enclosure at the beam end. The mice were
habituated to the task for three consecutive days before the test
day. Each day of the habituation period, the animals were placed
30, 60, and 100 cm away from the enclosure and allowed to
traverse along the beam. On the test day, each mouse performed
two consecutive trials (2-min interval between trials) with a maxi-
mum given time of 2 min to complete the task (the nose entering
the box was taken as task completion). The test was video
monitored (Sony DCR-SX21E), and blinded offline analysis was
conducted (Observer XT 12, Noldus, the Netherlands) to
evaluate the average number of foot slips made from two consecu-
tive trials.
2.2.5 | Assessment of gait
Gait test was conducted to assess the cerebellar function of the ani-
mals (Patel & Hillard, 2001). In this test, the hind paws of each mouse
were marked with a non-toxic ink, and the mouse was allowed to walk
on a white paper (50 × 10 cm) placed on the floor of a custom-made
plexiglass tunnel (50 × 10 × 10 cm). To obtain the left and right stride
length, the distance between two ipsilateral paw prints was measured,
whereas stride width was calculated from the distance between a foot
print and its contralateral stride length at right angle (Wecker et al.,
2013). The initial and last footprints were not considered in measure-
ments. All the animals were habituated to the test procedures and the
apparatus for 2 days prior to the test. On the day of test, two trials
were conducted for each animal to obtain mean stride length (left or
right) and width for that animal.
2.2.6 | Assessment of social interaction
The social interaction test was conducted in the home cage of test
mouse to assess the social behaviour of the animals (Sato,
Mizuguchi, & Ikeda, 2013). On test day, cage mate(s) were
removed from the home cage of the test mouse, and the mouse
remained in isolation for 15 min. A novel WT mouse of same
strain, same sex, and similar weight to the test mouse was then
introduced to the home cage of the test mouse. Activity was video
recorded (Sony DCR-SX21E) for 10 min, and the obtained video
files were blinded at the end of all experiments. Time spent in
active interactions (e.g. close following, sniffing, allogrooming/social
grooming and mounting) and number of rearing (lifting the front
paws on the air) occasions were coded offline using Observer XT
12 (Noldus, the Netherlands). Aggressive behaviours were not con-
sidered as social interactions and were not coded. In this test, a
reduced social interaction is considered as autistic-like behaviour
(Sato et al., 2013), while increased rearing occasions is sign of
defensive escapes (Kaplan et al., 2017).
2.2.7 | Assessment of anxiety-like behaviours
The elevated plus maze (EPM) test was performed to assess the level
of anxiety in animals (Chen et al., 2017). The wooden test apparatus
consists of two closed arms (50 × 10 × 40 cm) and two open arms
(50 × 10 cm) connected via a central platform (10 × 10 cm) and raised
at a height of 50 cm above the floor. Each animal was placed on the
central platform facing towards an open arm. Activity was video
recorded (Swann SRDVR-16440H, UK) for 5 min. The video files were
blinded and coded offline at the end of all experiments using Observer
XT 12 (Noldus, the Netherlands). Time spent on open arms was
inversely related to the level of anxiety.
2.2.8 | Assessment of depression-like behaviour
The sucrose preference test was carried out to assess the depression-
like behaviour (Serova, Mulhall, & Sabban, 2017). The animals were
separately housed during this test. Here, 24 hr before the test, animals
were trained to drink from two bottles each containing 2% sucrose.
On the first day of test, the animals were provided with a pre-weighed
bottle of 2% sucrose and another containing a pre-weighed volume of
tap water. The positions of the bottles were swapped after 24 hr to
avoid any side preferences. After 48 hr, both bottles were weighed
and sucrose preference was calculated by using the following formula.
Sucrose preference %ð Þ= Sucrose consumption
Sucrose consumption +Water consumption
×100:
2.2.9 | Assessment of cognition
A radial arm maze (RAM) consisting of eight arms (each arm
60 × 10 cm; raised at 50 cm above the floor) was used to assess the
reference memory and working memory (WM) of the animals. On four
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consecutive days, animals were given two 10-min sessions of habitua-
tion to the test apparatus and rules of the test, separated by a 90-min
interval. During the first 2 days of habituation, food rewards (1/4
Cheerios®, Nestle) were randomly scattered on the floor of the appa-
ratus covering all arms and food troughs at the end of each arm. On
the third and fourth habituation day, food rewards were placed only
in food troughs of four randomly selected arms (fixed for each animal
during the habituation and test day). Food was withdrawn 4–6 hr
before the trial (both during habituation and test days) to motivate
the animals to locate the rewards and thus perform the task. On the
test day, two trials of 10 min were conducted at 90-min interval and
the activity of the animals were video recorded for offline blinded
coding after the end of experiment. Entry to a non-baited arm was
considered as a reference memory error (RME), whereas re-entry to a
previously baited arm from which the food was already taken is
considered as a working memory error (WME). The mean working
memory error or reference memory error was calculated from the
two test trials.
2.3 | Statistical analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018).
In Study I, the welfare parameters were analysed using SPSS
24 (IBM SPSS Statistics®, UK; RRID:SCR_002865), while survival data
were analysed using GraphPad Prism 6 software (GraphPad Software,
Inc., USA; RRID:SCR_002798). Data obtained from welfare parame-
ters were compared using a three-way ANOVA to observe the main
effects of treatment, genotype and time, and their two-way and
three-way interactions. If significant two-way interactions were found,
Bonferroni post hoc tests were conducted on any Treatment × Geno-
type interactions to assess the effect of CBD treatment on different
genotypes (WT/Scn1a−/−). Bonferroni post hoc tests were also con-
ducted for any significant three-way Treatment × Genotype × Time
interactions to compare the effect of CBD treatment with vehicle
treatment at every time point of welfare assessment in both the WT
and Scn1a−/− groups. In all cases, post hoc analyses were corrected
for multiple comparisons. Data from 2.2% welfare scores were outliers
and were excluded from further analysis (±2.5*SD; Miller, 1991). For
the survival data, survival curves from Scn1a−/− vehicle-treated and
CBD-treated groups were compared using a Mantel–Cox test. No WT
animals died during the study, so survival curves were not compared.
All the data are expressed as mean ± SEM of n animals. In all cases,
P < .05 is considered as the level of significance.
In Study II, the data were analysed in GraphPad Prism 6 software
(RRID:SCR_002798). Survival curves of Scn1a+/− vehicle-treated and
Scn1a+/− CBD-treated group were compared using a Mantel–Cox test.
The percentage of animals from the Scn1a+/− vehicle-treated and
Scn1a+/− CBD-treated groups that survived until the end of the study
(P52) was compared by Fisher's exact test. Further, data obtained
from the co-morbidity assessment were checked for normality by
D'Agostino and Pearson omnibus normality test. Data obtained from
rotarod, gait, social interaction (active interaction), elevated plus maze,
sucrose preference, and radial arm maze (reference memory error)
tests were normally distributed and the differences between the three
groups were analysed by one-way ANOVA. If a significant difference
was found, then Holm–Sidak post hoc test was conducted among the
groups. On the other hand, data obtained from static beam, social
interaction (rearing occasions) and radial arm maze (working memory
errors) were found to be non-parametric, thus were analysed by
Kruskal–Wallis test. Upon observing a significant difference, the
Dunn's post hoc test was employed to compare the groups. Multiple
comparisons were corrected in all cases. Parametric data are pres-
ented in scattered dot plot in the figures and are expressed as
mean ± SEM. Non-parametric data are presented in box plot in the fig-
ures and are expressed as median, min to max, and interquartile range.
In all cases, n = the number of mice in an experimental group, and
P < .05 is considered as the level of significance.
2.4 | Materials
CBD with batch no. 6046727R (Study I) and 070214 (Study II) were
supplied by the GW Pharmaceuticals (Cambridge, UK). Ethanol and
Kolliphor® were purchased from Sigma-Aldrich (Poole, UK).
2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2017), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
3 | RESULTS
3.1 | Study I
3.1.1 | CBD improved neonatal welfare in
Scn1a−/− mice
In this study, animals (n = 10 per group) were treated with either vehi-
cle or CBD from P8 until P25 or death (whichever was earlier) and
welfare was monitored twice daily. The mean TNW scores in WT
vehicle-treated, WT CBD-treated, Scn1a−/− vehicle-treated and
Scn1a−/− CBD-treated groups were respectively 0.39 ± 0.04,
0.24 ± 0.04, 3.66 ± 0.04 and 2.85 ± 0.04. Main significant effects of
treatment where genotype and time, on TNW scores were found. A
significant three-way interaction among Treatment ×Genotype × Time
was observed, while significant two-way interactions were observed
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for Treatment × Genotype, Treatment × Time and Genotype × Time.
The post hoc comparison for Treatment × Genotype × Time interac-
tions revealed that CBD delayed significantly the worsening of
welfare scores in Scn1a−/− mice from P12 to P16 compared to the
vehicle-treated Scn1a−/− mice on respective days (Figure 2a). This post
hoc test further showed that CBD significantly improved TNW score
in WT animals from P8 to P8.5, that is, in first day of treatment
compared to the WT vehicle-treated animals on respective occasions
(Figure 2a).
3.1.2 | CBD improved survival in Scn1a−/− mice
As expected, none of the WT animals died during the study. In the
two Scn1a−/− groups, the median survival in the CBD-treated
Scn1a−/− mice was significantly higher (16.25 days) compared to the
vehicle-treated Scn1a−/− mice (15.5 days; Figure 2b).
3.2 | Study II
3.2.1 | CBD prevented premature mortality in
Scn1a+/− mice
The mortality rate was highest between P20 and P27 in Scn1a+/− mice
except for a single animal from the Scn1a+/− vehicle-treated group
which died at P47. We reviewed the recorded video footage and con-
firmed that tonic–clonic seizures were the cause of death in all cases.
Survival was significantly less in Scn1a+/− vehicle-treated group com-
pared to the Scn1a+/− CBD-treated group (Figure 3a). Approximately
66% (19 of 29) Scn1a+/− vehicle-treated animals died before the
F IGURE 2 Plots showing chronic administration of CBD to wild-type (WT) and Scn1a−/− mice on neonatal welfare (TNW) score and survival.
(A) Neonatal welfare score. CBD significantly improved the TNW score inWT mice from P8 to P8.5 compared to the vehicle-treatedWT mice.
CBD significantly improved the TNW score in Scn1a−/− mice from P12 onwards compared to the vehicle-treated Scn1a−/− mice. Data are
expressed as mean ± SEM; data were analysed by a three-way ANOVA with Bonferroni's post hoc test; #P < .05; *P < .05; #representsWT
vehicle-treated versusWT CBD-treated; *represents Scn1a−/− vehicle-treated versus Scn1a−/− CBD-treated. (b) Survival. CBD treatment
significantly (P < .05) increased survival compared to the vehicle-treated Scn1a−/− group. Error bars are SEM; data were analysed by Mantel–
Cox test
F IGURE 3 Plots showing chronic administration of CBD to Scn1a+/− mice on survival. (a) Survival of Scn1a+/− vehicle-treated and Scn1a+/−
CBD-treated group. CBD treatment significantly increased survival compared to the vehicle-treated Scn1a+/− group. Error bars are SEM; data
were analysed by Mantel–Cox test. (b) Percentage of Scn1a+/− vehicle-treated and Scn1a+/− CBD-treated animals that survived until the
completion of experiment (P52). A significantly greater number of CBD treated animals survived until the end of experiment compared to the
Scn1a+/− vehicle-treated animals. Data were analysed by Fisher's exact test. *P < .05
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completion of the study in contrast to only 17% (two of 12) Scn1a+/−
CBD-treated animals (Figure 3b). In total, 15 mice died during the dark
(active) cycle, and six died during the light (inactive) cycle.
3.2.2 | CBD did not exert any adverse effect on
motor function
Motor function was assessed by both the accelerating rotarod and
static beam test. In the accelerating rotarod test, no significant differ-
ence in time spent on rod was observed between the groups
(Figure 4a).
On the other hand, in the static beam test, a significant
difference in number of foot slips was found among the groups.
Scn1a+/− vehicle-treated group made significantly more foot slips
compared to the WT vehicle-treated group, however no significant
difference was observed in between Scn1a+/− vehicle-
treated and Scn1a+/− CBD-treated groups (Figure 4b). A further
comparison between the WT vehicle-treated and the Scn1a+/−
CBD-treated groups revealed no significant difference in number of
foot slips between these two groups (P = .48).
3.2.3 | CBD did not produce any gait abnormalities
In the gait test, no significant change was observed for left stride
length (Figure 4c), right stride length (Figure 4d) and stride width
(Figure 4e), between the three groups.
F IGURE 4 Dot plots or box and whisker plots showing chronic administration of CBD to Scn1a+/− mice on motor function and gait. (a) Mean
time (seconds) spent on accelerated rotarod by the wild-type (WT) vehicle-treated (n = 11), Scn1a+/− vehicle-treated (n = 11) and Scn1a+/− CBD-
treated (n = 10) groups. No difference was observed among the groups. (b) Median number of foot slips made in static beam test. CBD treatment
had no adverse effect on foot slips. (c) There were no significant differences in mean left stride length (millimetres) (d) mean right stride length
and (e) mean stride width among the groups. All the data are expressed as mean ± SEM except foot slips which are expressed as median, min to
max and interquartile range (IQR). All data except foot slips were analysed by one-way ANOVA with Holm–Sidak's post hoc test; foot slips data
obtained from static beam test were analysed by Kruskal–Wallis test followed by Dunn's multiple comparison test; *P < .05; NS, not significant
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3.2.4 | CBD improved social behaviour of Scn1a+/−
mice
The social interaction test was conducted to assess the active social
interaction and rearing behaviour exhibited in the home cage of the
test animals.
The time spent on active interaction was significantly differed
among the groups. The Scn1a+/− vehicle-treated animals (n = 11)
spent significantly less time in performing active interaction with the
stranger mouse compared to both WT vehicle-treated (n = 11) and
Scn1a+/− CBD-treated (n = 10) animals. The active interaction by the
Scn1a+/− CBD-treated group was similar to the WT vehicle-treated
group (P = .86).
On the other hand, a significant difference in number of rearing
events was observed among the groups, with a significantly higher
number of rearing occasions for Scn1a+/− vehicle-treated animals
compared to both WT vehicle-treated or Scn1a+/− CBD-treated ani-
mals (Figure 5b). No difference in rearing events was observed
between the WT vehicle-treated and Scn1a+/− CBD-treated groups
(P = .55).
3.2.5 | CBD reduced anxiety-like behaviour in
Scn1a+/− mice
The anxiety of the animals was assessed by the amount of the time
spent on the open arms of an elevated plus maze. The time spent on
the open arms differs significantly among the groups. The Scn1a+/−
vehicle-treated animals (n = 11; Figure 5c) spent significantly less time
on the open arms compared to both WT vehicle-treated (n = 11) and
Scn1a+/− CBD-treated (n = 10) animals. The time spent on the open
arms was not different between WT vehicle-treated and Scn1a+/−
CBD-treated groups (P = .73).
3.2.6 | CBD reduced depression-like behaviour in
Scn1a+/− mice
Depression-like behaviour is inversely correlated with sucrose prefer-
ence (Murray, Boss-Williams, & Weiss, 2013). In the present study,
sucrose preference differed significantly among the groups. Scn1a+/−
vehicle-treated animals (n = 11; Figure 5d) had a reduced preference
for sucrose in comparison to both WT vehicle-treated (n = 11) or
Scn1a+/− CBD-treated (n = 10 animals. Sucrose preference was
similar in between the WT vehicle-treated and Scn1a+/− CBD-treated
groups (P = .36).
3.2.7 | CBD improved cognition in Scn1a+/− mice
The reference memory and WM function in the animals were
assessed using an eight-arm radial arm maze test. A significant differ-
ence in the number of reference memory error was observed among
the groups. The Scn1a+/− vehicle-treated group (n = 10) made signifi-
cantly more reference memory error compared to both WT vehicle-
treated (n = 11) and Scn1a+/− CBD-treated (n = 10) groups (Figure 5e).
No difference in reference memory error was observed between the
WT vehicle-treated and Scn1a+/− CBD-treated groups (P = .65).
Further, working memory errors were significantly different
among the groups . The Scn1a+/− vehicle-treated group made signifi-
cantly more working memory errors compared to both WT vehicle-
treated and Scn1a+/− CBD-treated groups (Figure 5f). The working
memory errors was not differed in Scn1a+/− CBD-treated group com-
pared to theWT vehicle-treated group.
4 | DISCUSSION
We demonstrate for the first time that chronic administration of CBD
extends the survival and improves neonatal welfare of Scn1a−/− mice.
To our knowledge, CBD is the only drug to date which exerts such an
effect in this severe model of Dravet syndrome. Given the extreme
severity and early mortality observed in this model, it is not possible
to study intricate behavioural co-morbidities in the Scn1a−/− mice.
We therefore tested CBD using the Scn1a+/− mouse model of Dravet
syndrome to assess its effect on survival and behavioural co-morbid-
ities. Here, CBD prevented premature mortality and had a disease-
modifying action, improving social deficits, reducing anxiety-like and
depression-like behaviours and improving memory in the
Scn1a+/− mice.
In Study I, using the 129S Scn1a−/− knockout model, CBD did not
produce any adverse effect on neonatal welfare in WT mice
suggesting CBD is safe and well tolerated in healthy neonates. Indeed,
CBD actually improved neonatal welfare scores in these mice indicat-
ing that CBD provided significant protection against the severe motor
deficit and seizure associated deterioration of overall health in this
model. In the Scn1a−/− mice, CBD also improved other welfare param-
eters such as OT (indicator of pain) and BC score (overall health).
Vehicle-treated Scn1a−/− mice died prematurely as expected with this
severe epilepsy phenotype (Kalume et al., 2007; Yu et al., 2006) and
CBD treatment significantly extended their survival. This result is
remarkable as other AEDs, such as diazepam, have failed to extend
survival in this model with only hand-feeding previously observed to
extend survival (Yu et al., 2006). No differences in weight (see Data
S1) between CBD-treated Scn1a−/− mice and vehicle-treated Scn1a−/−
mice were seen and CBD induced extension of survival is therefore
unlikely to be due to increased feeding. We speculate that the exten-
sion of survival is due to the anticonvulsant and disease-modifying
properties of CBD, which also lacks the sedating effect of other anti-
convulsants used in this model. Indeed, a previous study has
established the anticonvulsant effect of CBD in a similar, but less
severe, model with haploinsufficiency of NaV1.1 channels (Kaplan
et al., 2017), a model which we adopted in Study II.
Given the positive results with CBD in the Scn1a−/− model of
Dravet syndrome, we then conducted a comprehensive investigation
into survival and co-morbidities associated with Dravet syndrome
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using the haploinsufficiency model of Dravet syndrome, the hybrid
Scn1a+/− heterozygote model. In this model, chronic CBD treatment
significantly increased the survival of Scn1a+/− mice in comparison to
their vehicle-treated counterparts; as tonic-clonic seizures (persisting
for less than a minute), were the reason for death in all Scn1a+/− mice,
we believe the lower mortality in CBD-treated group is evidence that
CBD provides protection against seizure related premature mortality.
This result is therefore consistent with a previous study using this
model where the anticonvulsant effect of CBD was demonstrated
(Kaplan et al., 2017). Sudden unexpected death in epilepsy (SUDEP) in
humans often occurs during sleep and is a common form of death in
childhood epilepsies such as Dravet (Purnell, Thijs, & Buchanan,
2018). However, our data indicate that the vast majority of animals
died during the active phase (dark cycle) indicating that death in this
model may not be a predictor of sudden unexpected death in epilepsy
in humans.
Seizures and premature mortality are not the only concern in
Dravet syndrome, co-morbidities such as motor deficits, including
abnormal gait are frequently reported (Aljaafari, Fasano, Nascimento,
Lang, & Andrade, 2017; Rilstone, Coelho, Minassian, & Andrade,
2012). Several AEDs used in Dravet syndrome such as phenobarbital,
valproic acid, phenytoin and lacosamide can also have adverse motor
effects in epileptic patients (Bainbridge et al., 2017; Ristic et al., 2006;
Zaccara, Perucca, Loiacono, Giovannelli, & Verrotti, 2013). In this
F IGURE 5 Dot plot or box and whisker plots showing
the effect of chronic administration of CBD to Scn1a+/−
mice on active social interaction, rearing, anxiety-like and
depression-like behaviours, and cognition. (a) Mean time
(seconds) spent on active interaction in social interaction
(SI) test by the wild-type (WT) vehicle-treated (n = 11),
Scn1a+/− vehicle-treated (n = 11), and Scn1a+/− CBD-
treated (n = 10) groups. CBD significantly increased the
active interaction time compared to the Scn1a+/− vehicle-
treated group. (b) Median number of rearing made in social
interaction test. CBD treatment significantly reduced the
number of rearing compared to the Scn1a+/− vehicle-
treated group. (c) Mean time (second) spent on open arms
in elevated plus maze (EPM) test. CBD treatment
significantly increased the time spent on the open arms of
EPM compared to the Scn1a+/− vehicle-treated group.
(d) Mean sucrose preference (%) in sucrose preference test.
CBD significantly increased the sucrose preference
compared to the Scn1a+/− vehicle-treated group. (e) Mean
reference memory errors (RMEs) inWT vehicle-treated
(n = 11), Scn1a+/− vehicle-treated (n = 10) and Scn1a+/−
CBD-treated (n = 10) groups in radial arm maze (RAM) test.
CBD significantly improved RME compared to the Scn1a+/−
vehicle-treated group. (f) Median working memory errors
(WMEs). CBD treatment significantly improved working
memory errors compared to the Scn1a+/− vehicle-treated
group. All the data are expressed as mean ± SEM except
rearing and working memory errors which are expressed as
median, min to max and interquartile range (IQR); all data
except rearing and working memory errors were analysed
by one-way ANOVA with Holm–Sidak's post hoc test;
rearing and working memory errors data obtained from
social interaction test and radial arm test respectively were
analysed by Kruskal–Wallis post hoc test followed by
Dunn's multiple comparison test; *P < .05
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study, CBD had no effect on motor function in either WT or Scn1a+/−
mice indicating that, unlike other AEDs used in treatment of Dravet,
CBD does not produce any motor deficits as measured by the acceler-
ating rotorod, static beam or gait analysis.
In addition to motor dysfunction, Dravet syndrome is linked to
several neuropsychiatric co-morbidities. For example, social deficits,
a feature common in autism, are often observed in Dravet syn-
drome (Berkvens et al., 2015; Li et al., 2011; Wolff, Casse-Perrot, &
Dravet, 2006). We investigated the effect of CBD on the social
behaviour of the Scn1a+/− mice. Vehicle-treated Scn1a+/− mice had
significant social deficits compared to their WT counterparts and
CBD-treated Scn1a+/− mice spent significantly more time in active
social interaction compared to their vehicle-treated counterparts.
These results are in line with the previous studies conducted in
this model where social interactions were impaired but restored by
stimulation of GABAA receptors (Han et al., 2012) and by a single
dose of CBD (Kaplan et al., 2017). While this is not the first study
to demonstrate that CBD can restore social interaction in a model
of Dravet syndrome, we are the first to demonstrate this at doses
shown to have anticonvulsant effects. We also demonstrate a
chronic CBD dosing regimen, similar to that used in Dravet syn-
drome therapy (Devinsky et al., 2017, 2018), improves social
interactions. Interestingly, CBD has been demonstrated to reduce
Δ9-tetrahydrocannabinol-induced (Malone, Jongejan, & Taylor,
2009) and MK-801-induced (Gururajan, Taylor, & Malone, 2012)
social deficits in rats, indicating this may be a generalised and
reproducible effect of CBD.
In addition to impaired social behaviour, anxiety and depression
are major problems for patients with Dravet syndrome (Chen et al.,
2018; Jain, Subendran, Smith, & Widjaja, 2018; Wang et al., 2018).
Although AEDs such as valproate, lamotrigine, clobazam, gabapentin
and oxcarbazepine have been reported to improve these behavioural
co-morbidities, a number of others have been shown to progressively
deteriorate them (Chen, Choi, et al., 2017). Anxiety/depression has
been previously reported the Dravet syndrome Scn1a+/− mouse model
(Han et al., 2012) and we observed anxiety-like behaviour in the ele-
vated plus maze in vehicle-treated Scn1a+/− mice, with animals spend-
ing significantly less time on the open arm compared to the WT
animals; CBD normalised this behaviour. Interestingly, Scn1a+/− mice
also displayed more rearing behaviours compared to the WT animals
in the social interaction tests which could be interpreted as a higher
level of anxiety compelling them to them try and escape the test situ-
ation (Mines, Yuskaitis, King, Beurel, & Jope, 2010). Again, CBD treat-
ment reduced this anxiety-like behaviour in Scn1a+/− mice. Together,
this illustrates that chronic CBD treatment has anxiolytic potential in
this model of Dravet syndrome. This is the first study to suggest an
anxiolytic effect of CBD in an epilepsy model. This is consistent with
reports of anxiolytic effects of CBD in a chronic unpredicted stress
model in mice using both elevated plus maze and novelty supressed
feeding test (Campos et al., 2013; Campos & Guimar~aes, 2009;
Fogaca, Campos, Coelho, Duman, & Guimaraes, 2018) where an
action of CBD to inhibit TRPV1, CB1 and CB2 was implicated respec-
tively. Anxiolytic effects of CBD have also been observed in a mouse
model of neuropathic pain where inhibition of 5-HT1A receptors was
implicated (De Gregorio et al., 2019).
To investigate depression-like behaviours, we employed the con-
ventional sucrose preference test in the Scn1a+/− mice (Serova et al.,
2017). This task is based on the assumption that depression-like
behaviour in rodents inversely correlates with sucrose preference
(Murray et al., 2013). Here, vehicle-treated Scn1a+/− mice showed
typical depression-like behaviour, that is, a reduced preference to
sucrose over water when compared to the WT mice with chronic
CBD-treatment normalising sucrose preference. An antidepressant-
like action of CBD has previously been documented in genetic (Shoval
et al., 2016), olfactory bulbectomy (Linge et al., 2016) and chronic
unpredictable stress (Campos et al., 2013) models of depression, but
we are the first to demonstrate such effect of CBD in any epilepsy
model. Although previous studies in naïve rodents have proposed that
CBD exerts an antidepressant action via modulating the 5-HT neuro-
transmission or endocannabinoid signalling (Campos et al., 2013;
Linge et al., 2016), the underlying pathology of depression in epilepsy
is complex and would necessitate a detailed mechanistic study to gain
a better understanding on any antidepressant effect of CBD.
Cognitive deficit is also a frequently reported co-morbidity in
Dravet syndrome patients (Acha, Perez, Davidson, & Carreiras, 2015;
Olivieri et al., 2016; Villeneuve et al., 2014); several domains of cogni-
tive functions including visual attention, executive functions, and ver-
bal, visual and working memories can be impaired in these patients
(Acha et al., 2015; Pascalicchio et al., 2007; Roebling et al., 2009).
Some AEDs including phenobarbital, phenytoin and topiramate nega-
tively impact cognition in people with epilepsy (Chen, Chi Chow, &
Lee, 2001; Mei, Montenegro, Guerreiro, & Guerreiro, 2006;
Wandschneider et al., 2017). Here, vehicle-treated Scn1a+/− mice
made significantly more reference memory errors and working mem-
ory errors compared to the WT mice in the radial arm maze indicating
the presence of spatial memory deficits. We showed that CBD
improved both the reference and WM function of Scn1a+/− mice com-
pared to their vehicle-treated counterparts, to our knowledge, the
first report of improving cognitive deficiencies in a model of Dravet
syndrome. We have previously reported a similar reversal of cognitive
deficits in a rat model of temporal lobe epilepsy (Patra et al., 2019),
which may suggest that CBD has a more generalised role in protecting
cognitive function in epilepsy, perhaps related to reduction in
seizure frequency or severity. Further to this spatial learning memory
deficits in a mouse model of Alzheimer's disease were attenuated
by CBD in a CB2 receptor-independent manner (Martin-Moreno
et al., 2011).
Several hypotheses have been proposed to explain the under-
lying pathology of memory impairment in epilepsy and seizure is a
contributory factor for cognitive decline during the developmental
process (Ben-Ari & Holmes, 2006; Khan, Zhao, Miller, & Holmes,
2010). This is consistent with the Dravet model used here as sei-
zures exhibited from an early age. Seizure-related disruption of
neural plasticity and cognition has also been demonstrated in other
animal models of epilepsies (Lenck-Santini & Scott, 2015; Schubert,
Siegmund, Pape, & Albrecht, 2005; Zhou, Lippman Bell, Sun, &
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Jensen, 2011). However, removing the cause of seizures does not
always restore cognitive deficits in people with epilepsy
(Helmstaedter, Kurthen, Lux, Reuber, & Elger, 2003). Strikingly, a
caregiver-reported quality of life in childhood epilepsy survey
stated an improved memory function in the patients with
refractory childhood epilepsy following CBD treatment (Rosenberg,
Louik, Conway, Devinsky, & Friedman, 2017). This is consistent
with the present study and illustrates the possibility that memory
impairment associated with epilepsy/Dravet syndrome may be
improved with chronic CBD treatment. We believe these findings
warrant further study in the Scn1a+/− model of Dravet Syndrome
to try and ascertain the molecular mechanisms underlying this
effect.
5 | CONCLUSION
We have established for the first time that the pharmaceutical formu-
lation of CBD (Epidiolex®; Epidyolex®; therefore, results cannot be
directly extrapolated to other CBD formulations) improves neonatal
welfare and extends survival in Scn1a+/− mice. This study is also the
first to demonstrate that chronic administration of CBD prevents pre-
mature mortality and improves several behavioural co-morbidities,
including impaired cognition and social interaction, associated with
the Scn1a+/− mouse Dravet syndrome model. These effects are with-
out the detrimental effects on motor function that are often seen with
current pharmacotherapy for this disorder. In light of the recent FDA
approval of CBD for treatment of Dravet syndrome in the United
States and by the EMA in the EU, we believe that the results obtained
from the present indicate that CBD may produce improvements in
Dravet syndrome therapy related to survival and co-morbidities in
addition to seizure control.
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